MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
Archive » 2005 » 2 » | Archive » Medical field » Fields » Dermatovenerology »

Recombinant Human Proteins – New Palette of Drugs for the Treatment of Psoriasis

 
Abstract:

This post is also available in: enEnglish slSlovenščina (Slovenian)

Psoriasis is a chronic, inflammatory disease, which is estimated to affect 2.5% of the world’s po­pulation. Clinically it is characterized by thickened, silvery white, scaly plaques, that can produce considerable discomfort and pain in patients. For the treatment of psoriasis are currently main­ly used corticosteroids, vitamin D analogs, ultraviolet A radiation and retinoids, all of which are nonspecific and unable to block the outbreak of disease. Advances in recombinant DNA technology and increased understanding of the pathophysiology of psoriasis have led to the development of numerous immunomodulatory drugs, which specifically inhibit the occur­rence of disease. Novel agents have direct effect on T cell, T cell activation, T cell migration, and expression of inflammatory mediators. However, they still cannot assure total remis­sion, but offer enhanced efficacy and improved safety. We have to take into consideration that treatment of psoriasis is usually longterm, meaning that adverse effects of a drug repre­sent a limiting factor for using that drug. In this article, known facts on psoriasis are presented, along with the review of therapies with stress on new immunomodulatory agents.

Authors:
Kristl Jernej

Keywords:
psoriasis, cytokine, recombinant proteins, monoclonal antibodies

Cite as:
Med Razgl. 2005; 44: 171–82.

Download PDF >>
© 2020 Društvo Medicinski razgledi | Na vrh strani / To top ↑